Media Center Banner Image


To eradicate CML


To identify and sponsor basic and clinical research in the field of CML


To improve the (1) funding of high-risk, high impact research not supported by other mechanisms, (2) understanding of the basic science of CML, (3) treatment of CML, and (4)quality of life of individuals with CML.

Total Appropriations

$22.05 million in FY02-06

Disease Background. CML also is known as chronic granulocytic leukemia or chronic myeloid leukemia. CML is a progressive disease characterized by an overgrowth of granulocytes, a type of white blood cell; its cause is unknown. CML accounts for about 14% of adult leukemias in Western countries. This year, approximately 4,500 individuals will be diagnosed with CML, and an estimated 900 individuals will die from the disease. In most cases, CML is characterized by a chromosomal abnormality known as the Philadelphia chromosome. Treatment usually consists of various chemotherapeutic agents used to disrupt the production of leukemic cells. These treatments may be followed by stem cell transplant. More recently, targeted therapy for CML with the Abl-specific tyrosine kinase inhibitor, STI571 (Gleevec™), has shown significant activity, including elimination of the causative genetic defect, in patients with advanced disease. However, genetic resistance to this therapy has been observed, indicating that research and the development of additional therapeutics are still needed.

Overview of the Program. The DOD CMLRP was established in FY02 by Joint Appropriations Conference Committee Report No. 107-350, which provided $5M for CML research. A stakeholders meeting was held to obtain input from scientific and consumer stakeholders on the major issues in CML research for use in formulating the CMLRP strategy. After the stakeholders meeting an Integration Panel, composed of CML scientific and consumer experts was constituted. This panel determined that the CMLRP's goal would be to support research leading to substantial improvement in the understanding, diagnosis, and treatment of chronic myelogenous leukemia (CML) and enhance the quality of life of persons with the disease. Research awards have been made using a two-tier review process composed of peer and programmatic reviews that ensures scientific merit and attainment of program goals. An important element in the execution of the CMLRP is the incorporation of advisors from the scientific, clinical, and consumer communities into the program who provide guidance on funding strategies and serve on both levels of review. The program's success encouraged Congress to appropriate additional funds to the CMLRP in subsequent years, totaling $22.05M through FY06. To date, the CMLRP has supported awards in four mechanisms: the Investigator-Initiated Research, Hypothesis Development, New Investigator and Therapeutic Development Awards. A total of 61 awards have been made through FY06.

Program Outcomes. The outcomes of CMLRP-funded research can be gauged in part by the number of resultant publications (84) and abstracts/presentations (120) reported by awardees to date. Details on each award funded are located on the CDMRP Website under Search Awards.

Research results focus primarily on etiology and alternative inhibitors of CML with potential for therapeutic development. Recent highlighted research is located in the 2007 Annual Report.

For more information, please contact
1 National Cancer Institute Physician Data Query and American Cancer Society - Facts and Figures 2006.
2 Ibid.